Explore the untapped potential of RNA amplifying therapeutics with the  CEO of CAMP4 Therapeutics, Josh Mandel-Brehm. We uncover the power of antisense oligonucleotides in rewriting the narrative for genetic diseases characterized by protein deficiency. Josh takes us behind the scenes of their innovative RNA Actuating Platform (RAP), a map charting the course of gene expression and a guide to the regulatory RNAs that can turn up the volume on genes gone silent due to disease. It&apos;s a pioneering journey through the promising avenues of metabolic disease treatment, with a special spotlight on their developmental star, CMP-CPS-001.First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. View the full transcript here. Interested in being featured as a guest on First In Human? Please reach out to owen@vial.com.? Stay in the Loop!For the latest news and updates, visit our website: https://vial.comFollow us on social media for real-time insights:Twitter: https://twitter.com/VialTrialsLinkedIn: https://www.linkedin.com/company/vialtrials

First In Human By Vial

Episode 62: Josh Mandel-Brehm - CEO, CAMP4 Therapeutics

Embark on a journey through the neurons and synapses of brain science with William Korinek, the CEO of Astrocyte Pharmaceuticals. In a conversation that fuses the molecular intricacies of neuroprotection with the humanistic pursuit of medical advancement, Bill reveals his unique path from molecular biologist to biotech innovator. Together, we unravel the complexities of securing funding, the importance of strategic networking, and the scarcity of research dollars for conditions impacting millions globally. His insights into the world of neuroprotection therapies, especially the uncharted potential of astrocytes, promise to leave you enlightened and curious about the future of neurological care.First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. Interested in being featured as a guest on First In Human? Please reach out to owen@vial.com.? Stay in the Loop!For the latest news and updates, visit our website: https://vial.comFollow us on social media for real-time insights:Twitter: https://twitter.com/VialTrialsLinkedIn: https://www.linkedin.com/company/vialtrials

Episode 61: William Korinek - CEO and Co-Founder, Astrocyte Pharmaceuticals

In this episode, Rachel Haines from Rinri Therapeutics joins us to discuss the possibilities of cell therapy for hearing loss. Our conversation with Rachel goes beyond just scientific innovation; we also explore the potential impact of Rinri&apos;s upcoming human trials, which are based on Professor Marcelo Rivolta&apos;s groundbreaking work. By delving into the challenges and excitement of pioneering clinical trials in uncharted territory, we envision a future where natural hearing restoration could become a reality.First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here.Interested in being featured as a guest on First In Human? Please reach out to owen@vial.com.? Stay in the Loop!For the latest news and updates, visit our website: https://vial.comFollow us on social media for real-time insights:Twitter: https://twitter.com/VialTrialsLinkedIn: https://www.linkedin.com/company/vialtrials

Episode 60: Rachel Haines - VP of Clinical Development & Operations, Rinri Therapeutics

Join as we dive deep into the world of oncology drug development with Bas van der Baan of Lixte. Discover the inspiration behind Lixte&apos;s focus on PP2A inhibitors and how this innovative approach is poised to revolutionize cancer treatment by enhancing chemotherapy and immunotherapy responses. Bas shares insights into ongoing clinical trials, regulatory considerations, and Lixte&apos;s ambitious long-term goals in expanding their impact on cancer care. Tune in to explore the cutting-edge science and vision driving Lixte&apos;s journey in the fight against cancer.First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here.Interested in being featured as a guest on First In Human? Please reach out to owen@vial.com.? Stay in the Loop!For the latest news and updates, visit our website: https://vial.comFollow us on social media for real-time insights:Twitter: https://twitter.com/VialTrialsLinkedIn: https://www.linkedin.com/company/vialtrials

Episode 59: Bas van der Baan - President & CEO, Lixte Biotechnology

Dr. Samar Mohanty, president and CSO of Nanoscope Therapeutics joins us to shed light on the revolutionary gene therapy that&apos;s giving hope to individuals with retinal degenerative diseases by pioneering a treatment that can re-sensitize the retina to detect low light levels. We open the curtains on their groundbreaking multi-characteristic opsins (MCOs), which have the potential to address all forms of retinal degeneration and restore vision in millions of visually impaired individuals.First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here.Interested in being featured as a guest on First In Human? Please reach out to owen@vial.com.? Stay in the Loop!For the latest news and updates, visit our website: https://vial.comFollow us on social media for real-time insights:Twitter: https://twitter.com/VialTrialsLinkedIn: https://www.linkedin.com/company/vialtrials

Episode 58: Samarendra Mohanty - President & CSO, Nanoscope Therapeutics

Imagine unlocking the secrets to revitalizing the brain&apos;s energy centers and turning the tide on neurodegenerative diseases. In this episode, Rob introduces us to CNM-Au8, an oral nanotherapeutic with the potential to recharge failing mitochondria. Our discussion traverses the innovative path Clene has charted, from the drug&apos;s conception to the exciting clinical trial results that highlight its capacity to enhance neurological functions and offer new hope to individuals grappling with ALS and multiple sclerosis.First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here.Interested in being featured as a guest on First In Human? Please reach out to owen@vial.com.? Stay in the Loop!For the latest news and updates, visit our website: https://vial.comFollow us on social media for real-time insights:Twitter: https://twitter.com/VialTrialsLinkedIn: https://www.linkedin.com/company/vialtrials

Episode 57: Rob Etherington- CEO and President at Clene Nanomedicine

Step into the future as Dr. Jason Bock, founder and CEO of CTMC discusses the company&apos;s unique approach to accelerating cell therapies from development to testing, and the power of collaboration in reshaping the future of cancer treatment. Listen in as we discuss how CTMC&apos;s partnership with MD Anderson is not just technical but deeply human in nature, with the patient and personalized medicine at heartFirst In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here.Interested in being featured as a guest on First In Human? Please reach out to catie@vial.com.? Stay in the Loop!For the latest news and updates, visit our website: https://vial.comFollow us on social media for real-time insights:Twitter: https://twitter.com/VialTrialsLinkedIn: https://www.linkedin.com/company/vialtrials

Episode 56: Jason Bock- Founder and CEO at CTMC

Embark on a quest to unravel the &apos;undruggable&apos; genome with Alex Federation, Co-founder of Talus Bio. Explore challenges in targeting transcription factors in cancer with Talus&apos;s innovative Marmot platform. Discover potential breakthroughs in rare diseases and pediatric cancers, and glimpse into the future of studying transcription factors within live human cells. First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here.Interested in being featured as a guest on First In Human? Please reach out to catie@vial.com.? Stay in the Loop!For the latest news and updates, visit our website: https://vial.comFollow us on social media for real-time insights:Twitter: https://twitter.com/VialTrialsLinkedIn: https://www.linkedin.com/company/vialtrials

Episode 55: Alex Federation- Co-Founder at Talus Bio

Join Dr. Ahmed Hamdy, CEO of Vincerx Pharma, on a compelling journey through oncology. From co-founding Acerta Pharma to pioneering patient-centric innovations, Dr. Hamdy shares his impactful career. Explore the groundbreaking VersAptxbioconjugation platform, designed to elevate cancer therapies and uncover the delicate balance between clinical excellence and commercial viability in the dynamic landscape of pharmaceuticals. First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here.Interested in being featured as a guest on First In Human? Please reach out to catie@vial.com.? Stay in the Loop!For the latest news and updates, visit our website: https://vial.comFollow us on social media for real-time insights:Twitter: https://twitter.com/VialTrialsLinkedIn: https://www.linkedin.com/company/vialtrials

Episode 54: Ahmed Hamdy- CEO at Vincerx Pharma

Have you ever considered the untapped potential of abandoned drugs? Join Dr. Sam Clark to discuss how his personal drive to combat mental illness is leading to breakthroughs in treatments for neurological and psychiatric diseases. Witness how Terran is not only resurrecting discarded medications for new purposes, but also pioneering the next generation of non-hallucinogenic psychedelic therapies aimed at tackling depression and Parkinson&apos;s psychosis. First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here.Interested in being featured as a guest on First In Human? Please reach out to catie@vial.com.? Stay in the Loop!For the latest news and updates, visit our website: https://vial.comFollow us on social media for real-time insights:Twitter: https://twitter.com/VialTrialsLinkedIn: https://www.linkedin.com/company/vialtrials

Episode 53: Sam Clark- CEO & Founder at Terran Biosciences

Ever wondered how technology could drastically improve early detection in healthcare? Let us take you on a journey with Mark McDonough, President and CEO of ChromaCode, as we unfold the world of molecular diagnostics with a special focus on HDPCR technology. Mark, with his diverse background in the military and healthcare, brings a fresh perspective to the table. He shares his unique insights on leadership and the challenges that come with introducing ground-breaking technologies in a traditional industry. First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here.Interested in being featured as a guest on First In Human? Please reach out to catie@vial.com.? Stay in the Loop!For the latest news and updates, visit our website: https://vial.comFollow us on social media for real-time insights:Twitter: https://twitter.com/VialTrialsLinkedIn: https://www.linkedin.com/company/vialtrials

Episode 52: Mark McDonough- President & CEO of ChromaCode

Embark on a journey through the intricate world of biotech with Bogdan Kezevic, co-founder and CEO of Kaleidoscope Bio, and uncover the revolutionary software shaping the future of scientific research. Bogdan&apos;s leap from scientist to entrepreneur has led to groundbreaking solutions for the challenges plaguing biotech. In our chat, he shares how data mismanagement and a disconnect in collaboration can cripple research efforts. With Kaleidoscope&apos;s software, teams can now navigate the complexities of their work with tools designed for clarity and focus, ensuring that the intricacies of science are met with a user-friendly interface.First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here.Interested in being featured as a guest on First In Human? Please reach out to catie@vial.com.? Stay in the Loop!For the latest news and updates, visit our website: https://vial.comFollow us on social media for real-time insights:Twitter: https://twitter.com/VialTrialsLinkedIn: https://www.linkedin.com/company/vialtrials

Episode 51: Bogdan Knezevic - Co-founder & CEO at Kaleidoscope.bio

What does it take to revolutionize the world of vaccines and touch lives across the globe? Join us on a riveting journey with Steven Reed, CEO and co-founder of HDT-Bio, as we explore the creation of the first refined tuberculosis vaccine and dive into the remarkable strides in RNA technology. This episode lifts the veil on the science that could redefine global health.First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here.Interested in being featured as a guest on First In Human? Please reach out to catie@vial.com.? Stay in the Loop!For the latest news and updates, visit our website: https://vial.comFollow us on social media for real-time insights:Twitter: https://twitter.com/VialTrialsLinkedIn: https://www.linkedin.com/company/vialtrials

Episode 50: Steven Reed - Co-Founder & CEO at HDT Bio

Join Jeffrey Bacha, a pioneer in the fight against cancer and the creative force behind Rakovina Therapeutics. For 25 years, Jeffrey has been reshaping the industry landscape, and today, he gives us a peek into his world of innovation. We venture into Rakovina&apos;s research and development of oncology drugs. exploring their groundbreaking technique combining PARP and HDAC inhibitors into a single molecule, a game-changer in enhancing synergy and reducing toxicity. First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here.Interested in being featured as a guest on First In Human? Please reach out to catie@vial.com.? Stay in the Loop!For the latest news and updates, visit our website: https://vial.comFollow us on social media for real-time insights:Twitter: https://twitter.com/VialTrialsLinkedIn: https://www.linkedin.com/company/vialtrials

Episode 49: Jeffrey Bacha - Chairman, Rakovina Therapeutics

Embark on a fascinating exploration of biotech entrepreneurship, guided by an expert who&apos;s been in the trenches: Jonathan Thon, CEO and founder of STRM.BIO. We&apos;ll give you an insider&apos;s view of his journey from academia to the cutting edge of biotech, unveiling his trailblazing work on platelet production and the transformative potential of extracellular vesicles in gene therapy. First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here.Interested in being featured as a guest on First In Human? Please reach out to catie@vial.com.? Stay in the Loop!For the latest news and updates, visit our website: https://vial.comFollow us on social media for real-time insights:Twitter: https://twitter.com/VialTrialsLinkedIn: https://www.linkedin.com/company/vialtrials

Episode 48: Jonathan Thon - Founder & CEO at STRM.BIO

First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO with episodes launching weekly on Tuesday's.? Stay in the Loop!For the latest news and updates, visit our website: https://vial.comFollow us on social media for real-time insights:Twitter: https://twitter.com/VialTrialsLinkedIn: https://www.linkedin.com/company/vialtrials

hubhopper

First In Human By Vial

hubhopper